SQZ Pipeline
SQZ APCs: Oncology
COMMERCIALIZATION RIGHTS:
SQZ-APC-HPV
HPV+ Solid Tumors
Next Gen SQZ APC
Solid and Liquid Tumors
SQZ-APC-X
Solid Tumors
SQZ APCs: Infectious Disease
COMMERCIALIZATION RIGHTS:
SQZ-APC-HBV
Chronic Hepatitis B Virus
SQZ-APC-RRV
Rapid Response Vaccines
SQZ AACs: Oncology
COMMERCIALIZATION RIGHTS:
SQZ-AAC-HPV
HPV+ Solid Tumors
SQZ-AAC-KRAS
KRAS mut Solid Tumors
Next Gen SQZ AAC
Solid and Liquid Tumors
SQZ TACs: Immune Tolerance
COMMERCIALIZATION RIGHTS:
SQZ-TAC-T1D
Type 1 Diabetes
SQZ-TAC-Biologics
Immune Response Mitigation
SQZ TAC-X
Multiple Diseases
The JDRF T1D Fund has invested in SQZ Biotech on multiple occasions to help progress the T1D program.